Conduction System Vs Surgical Left Ventricular Epicardial Pacing For Coronary Sinus Lead Failure
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
This a single-center, retrospective, observational study of patients that undergo coronary sinus(CS) lead revision, comparing epicardial lead placement to coronary sinus pacing(CSP) in those that had lead failure.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Official eligibility criteria
Inclusion Criteria: * All patients older than 18 years of age * Patients with HFrEF that underwent BVP-CRT * Experienced CS lead failure, whether initial or recurrent, subsequently replaced with transthoracic epicardial lead placement or CSP * Underwent Medtronic, Boston Scientific, or Abbott lead placement Exclusion Criteria: * Patients younger than 18 years of age * Transthoracic epicardial lead placement or CSP performed as the initial approach or for other reasons than lead replacement * Those for which CRT no longer provides symptom relief or mortality benefit.
Study sites (1)
KS
- Kansas City Heart Rhythm Institute · Overland Park, KS 66211Donita Atkins · Study contact · 816-651-1969 · Datkins@kchrf.comNaga Venkata K. Pothineni, MD · Principal investigatorMore trials in Overland Park